Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives


Author index

Page Path
HOME > Articles and issues > Author index
Hyun-kyung Oh 1 Article
COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021
Hyun-kyung Oh, Eun Kyeong Kim, Insob Hwang, Tae Eun Kim, Yeon-kyeong Lee, Eunju Lee, Yeon-Kyeng Lee
Osong Public Health Res Perspect. 2021;12(4):264-268.   Published online August 13, 2021
  • 6,094 View
  • 145 Download
  • 7 Web of Science
  • 6 Crossref
AbstractAbstract PDF
On February 26, 2021, coronavirus disease 2019 (COVID-19) vaccination was started for high-priority groups based on the recommendation of the Advisory Committee on Immunization Practices with 2 available COVID-19 vaccines (AstraZeneca and Pfizer-BioNTech) in Korea. This report provides a summary of adverse events following COVID-19 vaccination as of April 30, 2021.
Adverse events following immunization are notifiable by medical doctors to the Korea Immunization Management System (KIMS) under the national surveillance system. We analyzed all adverse events reports following COVID-19 vaccination to the KIMS from February 26 to April 30, 2021.
In total, 16,196 adverse events following 3,586,814 administered doses of COVID-19 vaccines were reported in approximately 2 months (February 26 to April 30, 2021). Of these, 15,658 (96.7%) were non-serious adverse events, and 538 (3.3%) were serious adverse events, including 73 (0.5%) deaths. The majority of adverse events (n=13,063, 80.7%) were observed in women, and the most frequently reported adverse events were myalgia (52.2%), fever (44.9%), and headache (34.9%). Of the 73 deaths following the COVID-19 vaccination, none were related to the vaccines.
By April 30, 3.6 million doses of the COVID 19 vaccine had been given in Korea, and the overwhelming majority of reports were for non-serious events. The Korea Disease Control and Prevention Agency continues to monitor the safety of COVID-19 vaccination.


Citations to this article as recorded by  
  • A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran
    Shahin Soltani, Behzad Karami Matin, Mohammad Mehdi Gouya, Sayed Mohsen Zahraei, Ghobad Moradi, Omid Chehri, Moslem Soofi, Mehdi Moradinazar, Fatemeh Khosravi Shadmani, Mahsa Kalantari, Hamidreza Khajeha, Mohammad Hassan Emamian, Farid Najafi
    BMC Public Health.2023;[Epub]     CrossRef
  • Herpes Zoster Reactivation After mRNA and Adenovirus-Vectored Coronavirus Disease 2019 Vaccination: Analysis of National Health Insurance Database
    Jin Gu Yoon, Young-Eun Kim, Min Joo Choi, Won Suk Choi, Yu Bin Seo, Jaehun Jung, Hak-Jun Hyun, Hye Seong, Eliel Nham, Ji Yun Noh, Joon Young Song, Woo Joo Kim, Dong Wook Kim, Hee Jin Cheong
    The Journal of Infectious Diseases.2023; 228(10): 1326.     CrossRef
  • Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
    Young June Choe, Seonju Yi, Insob Hwang, Jia Kim, Young-Joon Park, Eunhee Cho, Myoungyoun Jo, Hyunju Lee, Eun Hwa Choi
    Vaccine.2022; 40(5): 691.     CrossRef
  • Direct and Indirect Associations of Media Use With COVID-19 Vaccine Hesitancy in South Korea: Cross-sectional Web-Based Survey
    Minjung Lee, Myoungsoon You
    Journal of Medical Internet Research.2022; 24(1): e32329.     CrossRef
  • Self-Reported COVID-19 Vaccines’ Side Effects among Patients Treated with Biological Therapies in Saudi Arabia: A Multicenter Cross-Sectional Study
    Lama T AlMutairi, Wesal Y Alalayet, Sondus I Ata, Khalidah A Alenzi, Yazed AlRuthia
    Vaccines.2022; 10(6): 977.     CrossRef
  • COVID-19 vaccine safety monitoring in Republic of Korea from February 26, 2021 to October 31, 2021
    Insob Hwang, Kyeongeun Park, Tae Eun Kim, Yunhyung Kwon, Yeon-Kyeng Lee
    Osong Public Health and Research Perspectives.2021; 12(6): 396.     CrossRef

PHRP : Osong Public Health and Research Perspectives